Kong Raises $100 Million to Accelerate Cloud Connectivity
8.2.2021 18:30:00 EET | Business Wire | Press release
Kong Inc., the cloud connectivity company, today announced it has closed $100 million in Series D funding, led by Tiger Global Management with participation from existing investors Index Ventures, CRV, GGV Capital and Andreessen Horowitz as well as new investor Goldman Sachs. This latest round brings Kong’s total funding to $171 million, tripling its valuation to $1.4 billion since the Series C round. Kong will use the capital to scale its go-to-market operations, grow world-class Engineering and Customer Experience teams, and accelerate cloud connectivity with its new SaaS-based Kong Konnect service connectivity platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005517/en/
Kong Co-Founders Augusto Marietti and Marco Palladino (Photo: Business Wire)
“The shift to digital and cloud has been revolutionary across all fronts, quickly propelling developer-led organizations and API-first companies to the forefront,” said John Curtius, partner at Tiger Global Management. “With impressive momentum, happy customers and strong market share, Kong is primed to help organizations meet the growing demands of this new digital reality and succeed in today’s cloud native world. We have been following the company closely for the past couple of years, and Kong is really starting to pull away from the rest of the pack.”
The fundraise follows a record year for Kong, marked by a significant increase in adoption of its flagship open source software – Kong Gateway – now exceeding 220 million total downloads and 1.5 million monthly active instances. The company added key Global 2000 companies such as Deutsche Telekom, Orange, Papa John’s and Siemens to its growing enterprise customer base, as well as tripled its small business and mid-market enterprise customers. In addition, Kong was recognized as an Inc. 5000 company and a Deloitte Technology Fast 500 company with 1,908% revenue growth over a three-year period.
“In 2020, we saw an explosion of data in motion and services as companies fast-tracked the release of new digital experiences in response to the pandemic,” said Augusto Marietti, CEO and co-founder of Kong Inc. “Software is truly becoming like a giant nervous system through millions of APIs and services. Kong is on a mission to become the spinal cord and backbone by building the cloud connectivity fabric of the future.”
IDC predicts that worldwide data will reach 175 zettabytes by 2025, with 49% of the data residing in the cloud. According to Gartner, cloud native platforms will serve as the foundation for more than three-quarters of new digital workloads by 2024. Kong Konnect, a full-stack service connectivity platform designed for cloud native applications and delivered as a service, enables developers, architects and operators to seamlessly deliver connectivity at the edge, within their applications and between applications. It provides universal service connectivity and management that is reliable, observable and secure across any infrastructure.
“Modern infrastructure is driven by open source technologies, and Kong’s open source DNA has played a pivotal role in driving its adoption both in the community and in enterprise organizations,” said Marco Palladino, CTO and co-founder of Kong Inc. “Kong Konnect takes cloud connectivity to the next level by providing a full-stack service connectivity platform that goes from API gateways to services meshes via open technologies like Kong Gateway, CNCF’s Kuma and Insomnia – running across every cloud and every platform, including on Kubernetes and VMs. Teams around the world can now abstract away their enterprise L4-L7 connectivity in one click to build secure, resilient and distributed applications like never before.”
Additional Resources
About Kong Inc.
Kong creates software and managed services that connect APIs and microservices natively across and within clouds, Kubernetes, data centers and more using intelligent automation. Built on an open source core, Kong’s service connectivity platform enables digital innovation by allowing organizations to reliably and securely manage the full lifecycle of APIs and services for modern architectures, including microservices, serverless and service mesh. By providing developer teams with unprecedented architectural freedom, Kong accelerates innovation cycles, increases productivity, and seamlessly bridges legacy and modern systems and applications. For more information about Kong, please visit https://konghq.com or follow @thekonginc on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005517/en/
Contact information
Pauline Louie, Kong, (628) 243-7512, press@konghq.com
Jill Reed, Sift Communications for Kong, kong@siftpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom